The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 11107 malaria professionals are enjoying the free benefits of MalariaWorld today

mosquirix™

Isolation and light chain shuffling of a Plasmodium falciparum AMA1-specific human monoclonal antibody with growth inhibitory activity

January 13, 2021 - 10:14 -- Open Access
Author(s): 
Melanie Seidel-Greven, Otchere Addai-Mensah, Rolf Fendel, et al.
Reference: 
Malaria Journal 2021 20:37, 11 January 2021

Plasmodium falciparum, the parasite causing malaria, affects populations in many endemic countries threatening mainly individuals with low malaria immunity, especially children. Despite the approval of the first malaria vaccine Mosquirix™ and very promising data using cryopreserved P. falciparum sporozoites (PfSPZ), further research is needed to elucidate the mechanisms of humoral immunity for the development of next-generation vaccines and alternative malaria therapies including antibody therapy. A high prevalence of antibodies against AMA1 in immune individuals has made this antigen one of the major blood-stage vaccine candidates.

Subscribe to RSS - mosquirix™